Baseline characteristics
| Low dose Spironolactone 50 mg | High dose+ Spironolactone 100 mg+3 g potassium chloride | |
| N=10* | N=10 | |
| Female sex, n (%) | 8 (80) | 9 (90) |
| Age (years), mean±SD | 36.9±11.9 | 41.5±6.9 |
| BMI, mean±SD | 24.7±2.6 | 23.2±5.5 |
| Spironolactone dose (mg/kg) | 0.73±0.14 | 1.57±0.27 |
| Genetics, n (%) | ||
| LQTS1 | 3 (30) | 5 (50) |
| LQTS2 | 7 (70) | 5 (50) |
| Proband, n (%) | 2 (20) | 6 (60) |
| ICD, n (%) | 0 (0) | 2 (20) |
| Syncope/VT, n (%) | 1 (10) | 4 (40) |
| Sudden cardiac death in family before 60 years of age, n (%) | 5 (50) | 1 (10) |
| Beta-blocker treatment | ||
| Metoprolol, n (%) | 7 (70) | 6 (60) |
| Dose (mg), mean±SD | 86±24, 70 | 96±40 |
| Atenolol, n (%) | 3 (30), 73 | 3 (30), 67 |
| Dose (mg), mean±SD | 33±14 | 50±0 |
| Nebivolol, n (%) | 0 (0) | 1 (10) |
| Dose (mg),mean±SD | 2.5±0 | |
*Including the patient who did not complete treatment due to side effects.
BMI, body mass index; ICD, implantable cardioverter defibrillator; VT, ventricular tachycardia.